Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) Income towards Parent Company (2016 - 2025)

Haemonetics has reported Income towards Parent Company over the past 17 years, most recently at $44.8 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 19.35% year-over-year to $44.8 million; the TTM value through Dec 2025 reached $175.5 million, up 34.88%, while the annual FY2025 figure was $167.7 million, 42.63% up from the prior year.
  • Income towards Parent Company for Q4 2025 was $44.8 million at Haemonetics, up from $38.7 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $58.0 million in Q1 2025 and troughed at -$11.0 million in Q2 2021.
  • A 5-year average of $27.5 million and a median of $32.1 million in 2022 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: tumbled 162.61% in 2021 and later soared 546.65% in 2022.
  • Year by year, Income towards Parent Company stood at $14.9 million in 2021, then surged by 121.76% to $32.9 million in 2022, then fell by 5.17% to $31.2 million in 2023, then rose by 20.09% to $37.5 million in 2024, then rose by 19.35% to $44.8 million in 2025.
  • Business Quant data shows Income towards Parent Company for HAE at $44.8 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.